左炔诺孕酮宫内缓释系统治疗子宫内膜异位症对其CA125、hs-CRP及VEGF水平的影响

Effects of levonorgestrel intrauterine sustained-release system on CA125,hs-CRP and VEGF levels in endometriosis patients

目的分析子宫内膜异位症采用左炔诺孕酮宫内缓释系统(曼月乐)治疗的临床价值。方法选取64例子宫内膜异位症患者,根据随机数字表法分为对照组(采用米非司酮治疗)与研究组(采用曼月乐治疗),每组32例。对比两组临床疗效。结果研究组的总有效率(96.88%)明显高于对照组(81.25%)(P<0.05)。两组血管内皮生长因子(VEGF)、可溶性细胞间黏附分子-1(sICAM-1)、癌抗原125(CA125)和超敏C反应蛋白(hs-CRP)指标对比,差异有统计学意义(P<0.05)。研究组排卵、月经恢复正常时间短于对照组,痛经评分低于对照组(P<0.05)。研究组治疗后6个月、1年的复发率均低于对照组(P<0.05)。结论曼月乐治疗子宫内膜异位症可改善患者临床症状及性激素水平,调节机体血清指标,避免疾病反复发作,值得临床推广。

Objective To analyze the clinical value of levonorgestrel intrauterine sustained-release system(Mirena)for endometriosis.Methods 64 patients with endometriosis were selected and divided into control group(treated with mifepristone)and study group(treated with Mirena)according to random number table method,with 32 cases in each group.The clinical efficacy of the two groups was compared.Results The total effective rate of study group(96.88%)was significantly higher than that of control group(81.25%)(P<0.05).The indexes of vascular endothelial growth factor(VEGF),soluble intercellular adhesion molecule-1(sICAM-1),cancer antigen 125(CA125)and hypersensitive C-reactive protein(hs-CRP)were compared between the two groups,and the differences were statistically significant(P<0.05).The time of ovulation and menstruation return to normal in the study group was shorter than that in the control group,and the dysmenorrhea score was lower than that in the control group(P<0.05).The recurrence rates of 6 months and 1 year in the study group were lower than those in the control group(P<0.05).Conclusion Mirena in the treatment of endometriosis can improve the clinical symptoms and sex hormone levels of patients,regulate the serum index of the body,and avoid repeated attacks of the disease,which is worthy of clinical promotion.